Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02464059 · ClinicalTrials.gov registry record · Phase 2
Cathelicidin and Vitamin D: Impact on Populations At-Risk and With COPD
A Phase 2 study of Pulmonary Disease, Chronic Obstructive, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
- 2
- Study locations
NCT02464059: Completed Phase 2 study of Pulmonary Disease, Chronic Obstructive, sponsored by University of North Carolina, Chapel Hill.
NCT02464059 is a Phase 2 study of Pulmonary Disease, Chronic Obstructive that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 23 participants, below the 1,044-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02464059, a Phase 2 study of Pulmonary Disease, Chronic Obstructive, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
- 2
- Study locations
Study Summary
This proposal will evaluate a potential mechanism of increased risk of lung function impairment, cathelicidin levels, as well as determine if vitamin D replacement can alter this pathway. This study will improve the understanding of factors which can lead to chronic lung disease. If effective, this application would also provide the justification to study vitamin D as a therapy to improve lung health.
Primary Outcome
Change from baseline to 8 weeks in bronchoscopic lavage lung cathelicidin levels after vitamin D supplementation (comparison between pre- and post-supplementation cathelicidin levels using paired t-tests for repeated measures)
Conditions Studied
Interventions
- DRUG Vitamin D3
Study Locations (2)
Maryland
- Johns Hopkins Clinical Research Unit - Baltimore
North Carolina
- Meadowmont Pulmonary Research Clinic - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2015-11-10 |
| Est. Completion | 2020-04-15 |
| Phase | Phase 2 |
What the finished NCT02464059 record still lists
NCT02464059 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 1,044-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Pulmonary Disease, Chronic Obstructive appearing as the primary indexed condition, and to 1 intervention - of which Vitamin D3 is the first listed.
NCT02464059 reports a single indexed study location in Maryland, North Carolina.
Frequently Asked Questions
What is clinical trial NCT02464059 about?
NCT02464059 is a clinical study titled "Cathelicidin and Vitamin D: Impact on Populations At-Risk and With COPD". This proposal will evaluate a potential mechanism of increased risk of lung function impairment, cathelicidin levels, as well as determine if vitamin D replacement can alter this pathway. This study will improve the understanding of factors which can lead to chronic lung disease. If effective, this ...
What is the current status of trial NCT02464059?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2015-11-10. Estimated completion is 2020-04-15.
What conditions does trial NCT02464059 study?
This clinical trial studies the following conditions: Pulmonary Disease, Chronic Obstructive.
What interventions are being tested in trial NCT02464059?
The interventions under investigation include: Vitamin D3 (DRUG).
Who is sponsoring clinical trial NCT02464059?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02464059 being conducted?
This trial has 2 study locations across Maryland, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Disease, Chronic Obstructive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02464059's enrollment target sits among peer trials
23 64th of 74 higher than 10 of 74 other Pulmonary Disease, Chronic Obstructive trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pulmonary Disease, Chronic Obstructive trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component
COMPLETED · Phase 2
-
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
COMPLETED · Phase 2
-
A Study To Assess Efficacy And Safety Of Different Doses Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
COMPLETED · Phase 2
-
A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients.
COMPLETED · Phase 2
-
Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients
COMPLETED · Phase 2
-
Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Patients With COPD.
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI